Targeting the Toughest Diseases  Por  arte de portada

Targeting the Toughest Diseases

De: Vertex Pharmaceuticals
  • Resumen

  • Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.
    Copyright 2022, Bloomberg Media Studios
    Más Menos
Episodios
  • Targeting Duchenne Muscular Dystrophy
    Dec 19 2022

    Before John Killian's toddler son was diagnosed with Duchenne muscular dystrophy (DMD), doctors told parents to simply take their children home and love them. The disease weakens the body's muscles and cognitive functions, which can lead to premature death. John’s son is now college-bound, thanks to the help of medical advancements that target the symptoms of the disease. Geneticist Dr. Alison McVie-Wylie and the research team at Vertex hope to move past only treating the symptoms of DMD by addressing the disease at its root cause. 

    Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.

     

    Featured guests:

    John Killian is the proud father of Sam Killian, who lives with DMD.

    Mena Scavina is a Neurologist and Clinical Director at Nemours Children's Health and a Clinical Care Team Advisor at Parent Project Muscular Dystrophy.

    Jon Rey-Hastie is the Co-Founder of Pathfinders Neuromuscular Alliance

    Dr. David Altshuler is the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.

     Alison McVie-Wylie is a Vice President leading the Duchenne muscular dystrophy research team at Vertex Pharmaceuticals.

    Read more about Vertex's approach to targeting Duchenne muscular dystrophy.
     

    Más Menos
    14 m
  • Targeting Pain
    Dec 5 2022

    Quána Madison is one of the millions of Americans living with chronic pain. Dressing herself or even showering can be excruciating. Dr. Paul Negulescu and the research team at Vertex are thinking differently about pain – they’re investigating potential non-opioid based treatment options that aim to target pain where it starts. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. 

     

    Featured guests:

    Quána Madison is an artist, mindfulness teacher, healing arts workshop facilitator, self-leadership coach, model and artist-philanthropist. She lives with chronic pain.

    Norm Buckley is the Scientific Director of the Michael G. DeGroote Institute for Pain Research and Care at McMaster University. 

    David Altshuler is the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.

    Paul Negulescu is a renowned cystic fibrosis researcher and now the Senior Vice President leading the team researching pain at Vertex Pharmaceuticals.

    Read more about Vertex's approach to targeting pain.
     

    Más Menos
    12 m
  • Targeting Type 1 Diabetes
    Nov 21 2022

    Madison Carter is a fearless investigative reporter. She takes no day for granted because she lives with type 1 diabetes (T1D). Dr. Doug Melton is a world-renowned stem cell researcher and distinguished fellow at Vertex – and his now grown children, Sam and Emma, live with T1D. Along with scientists like Dr. Felicia Pagliuca, who leads Vertex’s research into T1D, he’s been on a quest to help Madison, Sam, Emma, and others like them by investigating the disease at a cellular level. 

    Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. 

     

    Featured guests:

    Madison Carter is an investigative journalist with 11Alive News, an NBC affiliate in Atlanta, GA. She's living with type 1 diabetes. 

    Aaron Kowalski is the President and CEO of JDRF. 

    Felicia Pagliuca is the Disease Area Executive, Type 1 Diabetes, at Vertex Pharmaceuticals

    Doug Melton leads investigations into treatments for Type 1 Diabetes at Vertex Pharmaceuticals. He is renowned for his stem cell research at Harvard University. Read more about Vertex's approach to targeting type 1 diabetes

    Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.

    Más Menos
    17 m

Lo que los oyentes dicen sobre Targeting the Toughest Diseases

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.